GLP1R and prostate cancer: A recent study by Bukavina et al. [5] analyzed a large claims-based clinical data set to investigate the association between GLP-1 receptor agonist use and the incidence of urologic cancers, including prostate cancer, kidney cancer, and bladder cancer, in patients with T2DM.